Welcome to the Master's of Microbial Biotechnology at North Carolina State University!
The MMB program presents a unique blend of science and business, mixed with real-world biotechnology projects and internships, to give you the experiences you need to become the biotechnology professional that you want to be!
The Professional Science Master’s degree in Microbial Biotechnology (MMB) at North Carolina State University --
View our most recent newsletter.
MMB Alumni work in a variety of companies such as The Hamner Institutes for Health Sciences, GlaxoSmithKline, and Novozymes.
Biotechnology in North Carolina, at NCSU, and in the News
North Carolina is ranked 3rd in the nation in number of biotech companies with over 500 companies employing more than 57,000 people. North Carolina's strong science, thriving industry and low cost of doing business offer biotechnology companies an opportunity like nowhere else in the world. The Research Triangle Park (RTP), a 7,000 acre development, is one of the oldest and largest science parks in North America and is home to more than 170 companies. For additional information on North Carolina's Biotechnology sector, please visit the North Carolina Biotechnology Center's website: www.ncbiotech.org.
Biotechnology in the news...
Forward genetic screens are powerful tools for the discovery and functional annotation of genetic elements. Recently, the RNA-guided CRISPR (clustered regularly interspaced short palindromic repeat)-associated Cas9 nuclease has been combined with genome-scale guide RNA libraries for unbiased, phenotypic screening. In this Review, we describe recent advances using Cas9 for genome-scale screens, including knockout approaches that inactivate genomic loci and strategies that modulate transcriptional activity. We discuss practical aspects of screen design, provide comparisons with RNA interference (RNAi) screening, and outline future applications and challenges.
With the latest CRISPR/Cas9 advance, the exhortation “turn on, tune in, drop out” comes to mind. The CRISPR/Cas9 gene-editing system was already a well-known means of “tuning in” (inserting new genes) and “dropping out” (knocking out genes). But when it came to “turning on” genes, CRISPR/Cas9 had little potency. That is, it had demonstrated only limited success as a way to activate specific genes... read more.
More from Nature Biotechnology.